Lilly ties a Zepbound campaign to a summer movie release

Eli Lilly has named actress and comedian Kym Whitley as a new patient spokesperson for Zepbound, its tirzepatide-based weight-loss drug, timing the announcement to Whitley's press tour for "Happy Gilmore 2," the sequel to the 1996 comedy in which she co-stars alongside Adam Sandler.^[1]

Whitley shared her story in a Q&A posted on Lilly's Zepbound patient website, describing years of trying different weight-management approaches before friends told her about the drug and she asked her doctor about it.^[1] "What helped me break that cycle of weight loss and regain was having a tool like Zepbound that supported the changes I was already making with diet and exercise," she said.^[1]

In the same materials, Whitley repeatedly frames Zepbound as a supplement to lifestyle changes rather than a stand-alone fix, language that mirrors the drug's FDA label, which requires the medication be used alongside a reduced-calorie diet and increased physical activity.^[1] "This isn't an overnight fix," she said. "It's a tool. You still have to do the work. You still have to eat right, get your nutrients in, and move your body."^[1]

Whitley appears to be Lilly's first official celebrity spokesperson specifically for Zepbound, though other well-known figures, including actor Harvey Fierstein, have spoken publicly about using GLP-1 drugs since Zepbound's 2023 approval.^[1] Her account joins other patient stories already featured on Lilly's consumer site for the drug.^[1] The company also recently signed "Modern Family" actor Eric Stonestreet, along with his mother, for a musical campaign promoting Mounjaro, Lilly's related tirzepatide drug approved for Type 2 diabetes.^[1]

The Whitley partnership arrives as Lilly has also been cutting prices to widen access to Zepbound, including adding single-dose vials of its highest dose strengths at $499 a month through its LillyDirect pharmacy.^[1]

Why it matters for patients

Celebrity endorsements and entertainment tie-ins are becoming a routine way that pharmaceutical companies introduce weight-loss drugs to a broad audience, rather than relying only on doctor referrals or traditional medical advertising.^[1] For patients or prospective patients, this means messaging about obesity treatment may increasingly appear alongside movie promotion and pop culture content, which can shape perceptions of what these drugs do and how well they work.^[1]

The source material notes that Whitley's own comments emphasize that Zepbound is meant to work with diet and exercise changes, not replace them, consistent with the drug's FDA labeling requirements.^[1] Patients weighing the accounts of celebrity spokespeople may want to keep in mind that these are paid partnerships promoting a specific product, and that individual results and experiences described publicly may not reflect typical outcomes; the source material does not provide clinical outcome data tied to Whitley's account.^[1]

The report also does not specify financial terms of the partnership or how long the campaign will run.^[1] It is not yet known from the available source how this specific campaign compares in scale to Lilly's broader GLP-1 marketing efforts or how regulators view these types of entertainment-linked promotions.

What happens next

Whitley's campaign coincides with the release of "Happy Gilmore 2," in which she has a role, and Lilly has said her story will remain featured on its Zepbound patient website alongside other patient accounts.^[1] The company has also continued lowering prices for Zepbound through its LillyDirect pharmacy, including single-dose vials at $499 a month for its highest dose strengths, though the source does not specify further planned price changes or additional celebrity partnerships beyond the recent Mounjaro campaign with Eric Stonestreet.^[1]